Fused heterocyclic ring compounds and method of treating retinal disease using same
US10501473B2 · kind B2 · utility
0Cited by
0References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 27, 2017 |
| Grant date | Dec 10, 2019 |
| Priority date | — |
| Expiry date | Jan 29, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA23V2002/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a novel indene derivative, a preparation method for the same, and a pharmaceutical composition for treating retinal disease comprising the same as an active ingredient. The novel indene derivative of the present invention, the optional isomer of the same, or the pharmaceutically acceptable salts of the same have excellent inhibitory efficiency of receptor-interacting serine-threonine-protein kinase 1 (RIPK1). Therefore, the composition containing the same as an active ingredient can be effectively used as a pharmaceutical composition for treating retinal disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.